Abstract
Olanzapine-induced dyslipidemia significantly increases the risk of cardiovascular disease in patients with schizophrenia. However, the clinical features of olanzapine-induced dyslipidemia remain hitherto unclear because of inconsistencies in the literature. This meta-analysis thus investigated the effects of olanzapine treatment on lipid profiles among patients with schizophrenia. Studies of the effects of olanzapine on lipids were obtained through the PubMed, Web of science, The Cochrane Library and Embase databases (up to January 1, 2020). Twenty-one studies and 1790 schizophrenia patients who received olanzapine therapy were included in our analysis. An olanzapine-induced increase was observed in plasma triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels in patients with schizophrenia (all P < 0.05). Moreover, the time points analyzed included the following: baseline, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and ≥ 24 weeks (data of ≥ 24 weeks were integrated). The significant elevation of TG, TC, and LDL-C was observed in patients with schizophrenia already by 4 weeks of olanzapine therapy (all P < 0.05), with no obvious changes observed in high-density lipoprotein cholesterol (HDL-C) (P > 0.05). In conclusion, olanzapine-induced dyslipidemia, characterized by increased TG, TC, and LDL-C levels, was observed in patients with schizophrenia already by 4 weeks of olanzapine treatment.
Highlights
Olanzapine-induced dyslipidemia significantly increases the risk of cardiovascular disease in patients with schizophrenia
The analysis indicated that olanzapine-induced dyslipidemia is characterized by increases of TG, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) and no changes in high-density lipoprotein cholesterol (HDL-C)
In this current meta-analysis of 21 studies on the effects of olanzapine on lipid profiles in patients with schizophrenia, we demonstrated that the clinical features of dyslipidemia were characterized by an elevation of TG, TC, and LDL-C, with no significant changes in HDL-C
Summary
Olanzapine-induced dyslipidemia significantly increases the risk of cardiovascular disease in patients with schizophrenia. The clinical features of olanzapine-induced dyslipidemia remain hitherto unclear because of inconsistencies in the literature This meta-analysis investigated the effects of olanzapine treatment on lipid profiles among patients with schizophrenia. An olanzapine-induced increase was observed in plasma triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels in patients with schizophrenia (all P < 0.05). Some clinical randomized trials have reported increased serum triglyceride (TG) levels in schizophrenic patients on olanzapine therapy, the changes in total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), and low-density lipoprotein cholesterol (LDL-C) remain a matter of d ispute[7,8,9,10,11]. We further analyzed the influence of clinical characteristics and treatment duration on olanzapine-induced dyslipidemia in patients with schizophrenia
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
